Article
Multidisciplinary Sciences
Yelena Y. Janjigian, Akihito Kawazoe, Patricio Yanez, Ning Li, Sara Lonardi, Oleksii Kolesnik, Olga Barajas, Yuxian Bai, Lin Shen, Yong Tang, Lucjan S. Wyrwicz, Jianming Xu, Kohei Shitara, Shukui Qin, Eric Van Cutsem, Josep Tabernero, Lie Li, Sukrut Shah, Pooja Bhagia, Hyun Cheol Chung
Summary: The study results demonstrate that adding pembrolizumab to trastuzumab and chemotherapy significantly reduces tumor size, induces complete responses in some patients, and improves objective response rate in HER2-positive gastric or gastro-oesophageal junction adenocarcinoma.
Article
Nanoscience & Nanotechnology
Lihong Sun, Jinxia Zhang, Menghong Xu, Lulu Zhang, Qingshuang Tang, Jing Chen, Ming Gong, Suhui Sun, Huiyu Ge, Shumin Wang, Xiaolong Liang, Ligang Cui
Summary: The study developed ultrasound microbubbles (TP MBs) for targeted combination of sonodynamic therapy and antibody therapy, with in vivo delivery monitored by ultrasound/fluorescence bimodal imaging. TP MBs combined with ultrasound can increase the uptake of sonosensitizers and antibodies in tumor tissue, greatly enhancing the therapeutic effect on HER2-positive gastric cancer.
ACS APPLIED MATERIALS & INTERFACES
(2022)
Review
Oncology
Chenzhe Ma, Xiao Wang, Jiwu Guo, Bo Yang, Yumin Li
Summary: Gastric cancer is the fifth most common cancer worldwide, and the treatment of advanced gastric cancer has seen limited progress. Human epidermal growth factor receptor 2 (HER2) has been found to contribute to the prognosis and pathogenesis of various cancers. Trastuzumab has emerged as the first-line targeted medication for treating HER2-positive advanced gastric cancer, but trastuzumab resistance has become a significant issue. This review focuses on the drug mechanisms of HER2-targeted therapy for gastric cancer and new detection techniques.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Elisabeth S. Bergen, Lorenzo Pilla, Edouard Auclin, Ayseguel Ilhan-Mutlu, Gerald W. Prager, Filippo Pietrantonio, Maria Antista, Filippo Ghelardi, Debora Basile, Giuseppe Aprile, Raffaella Longarini, Vincent Hautefeuille, David Tougeron, Pascal Artru, May Mabro, Antoine Drouillard, Gael Roth, Meher Ben Abdelghani, Ines Clement, Clemence Toullec, Laurent Mineur, Rosine Guimbaud, Julien Taieb, Aziz Zaanan
Summary: The optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma remains challenging. This study showed that there was no additional benefit of adding fluoropyrimidine to trastuzumab monotherapy as a maintenance treatment. Reintroduction of initial therapy at first progression may be a feasible approach to prolong survival.
Article
Oncology
Stefano Ughetto, Cristina Migliore, Filippo Pietrantonio, Maria Apicella, Annalisa Petrelli, Laura D'Errico, Stefania Durando, Daniel Moya-Rull, Sara E. Bellomo, Sabrina Rizzolio, Tania Capeloa, Salvatore Ribisi, Maurizio Degiuli, Rossella Reddavid, Ida Rapa, Uberto Fumagalli, Stefano De Pascale, Dario Ribero, Carla Baronchelli, Giovanni Sgroi, Emanuele Rausa, Gian Luca Baiocchi, Sarah Molfino, Stefania Manenti, Maria Bencivenga, Michele Sacco, Claudia Castelli, Salvatore Siena, Andrea Sartore-Bianchi, Federica Tosi, Federica Morano, Alessandra Raimondi, Michele Prisciandaro, Annunziata Gloghini, Silvia Marsoni, Antonino Sottile, Ivana Sarotto, Anna Sapino, Caterina Marchio, Paola Cassoni, Simonetta Guarrera, Simona Corso, Silvia Giordano
Summary: This study demonstrates that in patients with HER2-amplified gastric cancer, a dual HER2 blockade is crucial for optimal efficacy, leading to complete and durable responses in most cases. A selected subpopulation of HER2-hyper-amplified GC patients could greatly benefit from this treatment strategy.
Article
Multidisciplinary Sciences
Yi Rao, Zachary Samuels, Lukas M. Carter, Sebastien Monette, Sandeep Surendra Panikar, Patricia M. R. Pereira, Jason S. Lewis
Summary: HER2 is overexpressed in various cancers. Combining trastuzumab with lutetium-177 can deliver radiation to gastric tumors with minimal toxicity. Lovastatin can enhance cell surface HER2 levels and improve the therapeutic efficacy of [177Lu]Lu-DOTA-trastuzumab.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2023)
Article
Oncology
Kyunghye Bang, Jaekyung Cheon, Young Soo Park, Hyung-Don Kim, Min-Hee Ryu, Yangsoon Park, Meesun Moon, Hyungeun Lee, Yoon-Koo Kang
Summary: This study analyzed data from 153 HER2-positive advanced gastric cancer patients and found that rescued HER2-positive patients had worse clinical outcomes than initially HER2-positive patients, especially those with an IHC score of 3+.
Article
Oncology
Tae-Hwan Kim, Hun Do Cho, Yong Won Choi, Hyun Woo Lee, Seok Yun Kang, Geum Sook Jeong, Jin-Hyuk Choi, Mi Sun Ahn, Seung-Soo Sheen
Summary: The study analyzed real-world data of patients with HER2-positive RPMGC treated with trastuzumab-based chemotherapy in a single center. The outcomes were comparable to the ToGA trial, and conversion surgery could be considered for suitable patients after a favorable response to chemotherapy.
Editorial Material
Oncology
Alicia F. C. Okines, Nicholas C. Turner
Summary: HER2 amplification heterogeneity is linked to resistance to trastuzumab emtansine in the neoadjuvant setting, highlighting the significance of determining whether varying HER2-positive cancer types require distinct treatment approaches.
Article
Oncology
Chihwan Cha, Sung Gwe Ahn, Dooreh Kim, Janghee Lee, Soeun Park, Soong June Bae, Jee Ye Kim, Hyung Seok Park, Seho Park, Seung Il Kim, Byeong-Woo Park, Joon Jeong
Summary: Adding pertuzumab to chemotherapy increased the axillary pathological complete response (pCR) rate in patients with clinically node-positive, HER2-positive breast cancer, while dual HER2 blockade did not elevate the axillary response. Breast pCR could be a strong predictor for axillary pCR in clinically node-positive patients treated with HER2-targeting therapy.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
Ivonne Haffner, Katrin Schierle, Elba Raimundez, Birgitta Geier, Dieter Maier, Jan Hasenauer, Birgit Luber, Axel Walch, Katharina Kolbe, Jorge Riera Knorrenschild, Albrecht Kretzschmar, Beate Rau, Ludwig Fischer von Weikersthal, Miriam Ahlborn, Gabriele Siegler, Stefan Fuxius, Thomas Decker, Christian Wittekind, Florian Lordick
Summary: Discrepancies in HER2 assessment in mGC were found in tumor specimens with intermediate HER2 expression. Borderline HER2 positivity and heterogeneity of HER2 expression should be considered as resistance factors for HER2-targeting treatment of mGC. HER2 thresholds should be reconsidered.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Shuo Wang, Yuze Zhao, Yuguang Song, Guoliang Qiao, Yan Di, Jing Zhao, Pingping Sun, Huixia Zheng, He Huang, Hongyan Huang
Summary: In gastric cancer, the expression of the ERBB2d16 isoform is associated with EMT, immunosuppression, and resistance to trastuzumab therapy. The ERBB2d16/ERBB2 ratio may serve as a prognostic marker for gastric cancer patients receiving trastuzumab therapy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Adam L. Maddox, Matthew S. Brehove, Kiarash R. Eliato, Andras Saftics, Eugenia Romano, Michael F. Press, Joanne Mortimer, Veronica Jones, Daniel Schmolze, Victoria L. Seewaldt, Tijana Jovanovic-Talisman
Summary: This study used quantitative single molecule localization microscopy to assess the molecular features of HER2 in a therapy-responsive setting and found that the nano-organization of HER2 could potentially serve as a signature of therapy-responsive disease.
Article
Multidisciplinary Sciences
Sandra Orru, Emanuele Pascariello, Barbara Pes, Vincenzo Rallo, Raffaele Barbara, Marta Muntoni, Francesca Notari, Gianfranco Fancello, Cristina Mocci, Maria Rosaria Muroni, Paolo Cossu-Rocca, Andrea Angius, Maria Rosaria De Miglio
Summary: In this study, the predictive and prognostic role of HER2 protein/gene expression levels combined with clinico-pathologic features in HER2+ breast cancer patients receiving trastuzumab-based neoadjuvant chemotherapy was evaluated. The study found that a high tumoral pathological complete response rate is associated with a high percentage of infiltrating immune cells and right-sided tumors, which reduce distant metastasis and improve survival. HER2 protein expression levels and tumor laterality emerge as strong predictors of tumoral pathological complete response.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Mirat Shah, Suparna Wedam, Joyce Cheng, Mallorie H. Fiero, Huiming Xia, Fang Li, Jianghong Fan, Xinyuan Zhang, Jingyu Yu, Pengfei Song, Wei Chen, Tiffany K. Ricks, Xiao Hong Chen, Kirsten B. Goldberg, Yutao Gong, William F. Pierce, Shenghui Tang, Marc R. Theoret, Richard Pazdur, Laleh Amiri-Kordestani, Julia A. Beaver
Summary: Tucatinib in combination with trastuzumab and capecitabine was approved by the FDA for the treatment of advanced HER2-positive breast cancer, with demonstrated efficacy in patients with brain metastases. The approval was based on data from the HER2CLIMB trial showing significant benefit in progression-free survival and overall survival.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Hana Kim, Soomin Ahn, Hongsik Kim, Jung Yong Hong, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Kyoung-Mee Kim, Seung Tae Kim
Summary: This study investigated the status of homologous recombination deficiency (HRD) in various solid tumor patients and found that HRD alone is not sufficient to predict the efficacy of immune checkpoint inhibitors (ICIs) in solid tumor patients.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Oncology
Bum Jun Kim, Hee-Jung Jee, Sun Young Rha, Hye Sook Han, Min-Hee Ryu, Se Hoon Park, Jong Gwang Kim, Woo Kyun Bae, Keun-Wook Lee, Do-Youn Oh, Ji-Hye Byun, Dong Sook Kim, Young Ju Suh, Hyonggin An, Dae Young Zang
Summary: In patients with HER2-positive gastric or gastro-esophageal junction adenocarcinoma, second-line treatment with ramucirumab plus paclitaxel showed a significantly higher objective response rate compared to patients with HER2-negative disease. However, the increased response to treatment did not correlate with an improvement in overall survival (OS).
Meeting Abstract
Oncology
Masatoshi Eto, Jae-Lyun Lee, Se Hoon Park, Norihiko Tsuchiya, Po-Jung Su, T. W. Chan, Chirag Jyotiker Desai, Alessandra Di Pietro, Jing Wang, Robert J. Laliberte, Seasea Gao, Howard Gurney
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Yohann Loriot, Petros Grivas, Ronald De Wit, Arjun Vasant Balar, Arlene O. Siefker-Radtke, Jakub Zolnierek, Tibor Csoszi, Sang Joon Shin, Se Hoon Park, Vagif Atduev, Mahmut Gumus, Yu-Li Su, Saziye Burcak Karaca, Hernan Cutuli, Mehmet Nahit Sendur, Calvin Jia, Karen O'Hara, Sonia Franco, Nobuaki Matsubara
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Ryul Kim, Jeeyun Lee, Ghee Young Kwon, Jung Yong Hong, Byong Chang Jeong, Se Hoon Park
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Hongsik Kim, Ryul Kim, Joohyun Hong, Ghee Young Kwon, Chan Kyo Kim, Won Park, Wan Song, Hyun Hwan Sung, Byong Chang Jeong, Jung Yong Hong, Se Hoon Park
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Sun Young Rha, Toni K. Choueiri, Vsevolod B. Matveev, Anna Alyasova, Sung-Hoo Hong, Teresa Alonso Gordoa, Howard Gurney, Georg A. Bjarnason, Tomas Buchler, Paolo Pedrazzoli, Toshio Takagi, Se Hoon Park, Jae-Lyun Lee, Rodolfo F. Perini, Cixin He, Jodi A. McKenzie, Masatoshi Eto
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Thomas Powles, Se Hoon Park, Eric Voog, Claudia Caserta, Begona Perez-Valderrama, Howard Gurney, Yohann Loriot, Srikala S. Sridhar, Norihiko Tsuchiya, Cora N. Sternberg, Joaquim Bellmunt, Jeanny B. Aragon-Ching, Daniel P. Petrylak, Andy Blake-Haskins, Robert J. Laliberte, Jing Wang, Nuno Matos Costa, Petros Grivas
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Stefan N. Symeonides, Jaroslav Hajek, Yen-Hwa Chang, Jae-Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross-Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Lei Xu, Kentaro Imai, Jacqueline Willemann-Rogerio, David I. Quinn, Thomas Powles
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Jonathan E. Rosenberg, Se Hoon Park, Tu V. Dao, Daniel E. Castellano, Jian-Ri Li, Som Mukherjee, Kathryn Howells, Hannah Dry, Mark C. Lanasa, Ross Stewart, Dean F. Bajorin
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Arlene O. Siefker-Radtke, Andrea Necchi, Se Hoon Park, Jesus Garcia-Donas, Robert A. Huddart, Earle F. Burgess, Mark T. Fleming, Arash Rezazadeh Kalebasty, Begona Mellado, Sergei Varlamov, Monika Joshi, Ignacio Duran, Scott T. Tagawa, Yousef Zakharia, Sydney Akapame, Ademi E. Santiago-Walker, Manish Monga, Anne O'Hagan, Yohann Loriot
Summary: This study evaluated the long-term efficacy and safety of Erdafitinib in patients with locally advanced or metastatic urothelial carcinoma. The results showed consistent activity and manageable safety profile in these patients.
Article
Urology & Nephrology
Hyun Hwan Sung, Hana Kim, Ryul Kim, Chan Kyo Kim, Ghee Young Kwon, Won Park, Wan Song, Byong Chang Jeong, Se Hoon Park
Summary: This study assessed the safety and efficacy of gemcitabine and cisplatin as neoadjuvant chemotherapy followed by selective bladder preservation chemoradiotherapy in muscle-invasive bladder cancer. The results showed that the approach was feasible and effective in the treatment of muscle-invasive bladder cancer.
INVESTIGATIVE AND CLINICAL UROLOGY
(2022)
Article
Oncology
Thomas Powles, Se Hoon Park, Eric Voog, Claudia Caserta, Begona P. Valderrama, Howard Gurney, Haralabos Kalofonos, Sinisa Radulovic, Wim Demey, Anders Ullen, Yohann Loriot, Srikala S. Sridhar, Norihiko Tsuchiya, Evgeny Kopyltsov, Cora N. Sternberg, Joaquim Bellmunt, Jeanny B. Aragon-Ching, Daniel P. Petrylak, Robert J. Laliberte, Bo Huang, Nuno Costa, John A. Blake-Haskins, Petros Grivas
Summary: This summary discusses the initial results of the JAVELIN Bladder 100 study, which investigated the use of avelumab as maintenance treatment for advanced urothelial cancer patients. The study found that patients treated with avelumab lived approximately 7 months longer on average compared to those who received standard supportive care alone.
Article
Biochemistry & Molecular Biology
Jun Su Park, Jeong Il Yu, Do Hoon Lim, Heerim Nam, Young Il Kim, Jeeyun Lee, Won Ki Kang, Se Hoon Park, Seung Tae Kim, Jung Yong Hong, Tae Sung Sohn, Jun Ho Lee, Ji Yeong An, Min Gew Choi, Jae Moon Bae
Summary: In this study, the clinical significance of preoperative hematological parameters in patients with advanced stomach cancer was investigated. The results showed that absolute monocyte count (AMC) was the most relevant prognostic factor for overall survival and recurrence-free survival. Furthermore, adjuvant concurrent chemoradiotherapy (CCRT) improved recurrence-free survival in patients with a high absolute lymphocyte count (ALC).
Article
Biochemistry & Molecular Biology
Joohyun Hong, Hyun Hwan Sung, Byong Chang Jeong, Se Hoon Park
Summary: The treatment of metastatic urothelial carcinoma after failure with platinum-based chemotherapy and immune checkpoint inhibitors remains controversial. This study found that participation in clinical trials and having a good performance status are associated with benefits from subsequent therapy for pretreated mUC.
